Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | FES | P07332 | 1/20 | 0.38 |
| ▸ | FER | P16591 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.38 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.38 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196006 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1GAAHPGDMAPK1 | |
| SCHEMBL423096 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1GAAHPGDMAPK1 | |
| SCHEMBL427740 | 0.89 | GAA (0.42) | KDM4EALDH1A1GAAHPGDMAPK1 | |
| SCHEMBL427739 | 0.89 | GAA (0.42) | KDM4EALDH1A1GAAHPGDMAPK1 | |
| SCHEMBL10196557 | 0.89 | GAA (0.42) | KDM4EALDH1A1GAAHPGDMAPK1 | |
| SCHEMBL429379 | 0.89 | L3MBTL1 (0.39) | KDM4EALDH1A1GAAHPGDSYK | |
| SCHEMBL10198827 | 0.89 | L3MBTL1 (0.39) | KDM4EALDH1A1GAAHPGDSYK | |
| SCHEMBL429378 | 0.89 | L3MBTL1 (0.39) | KDM4EALDH1A1GAAHPGDSYK | |
| SCHEMBL13759284 | 0.86 | KDM4E (0.43) | KDM4EALDH1A1GAAHPGDMAPK1 | |
| SCHEMBL427061 | 0.85 | USP2 (0.46) | KDM4EALDH1A1HPGDSYKTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263764-B2 | IL-12 Modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-11 | — | — | US | claimed |
| US-7863270-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-04 | — | — | US | claimed |
| US-20060281711-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-12-14 | — | — | US | claimed |
| WO-2006124662-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-11-23 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8263764-B2 | IL-12 Modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7863270-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060281711-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | KDM4E 3825/4885ALDH1A1 1903/4885GAA 2575/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | KDM4E 1015/4885ALDH1A1 3468/4885GAA 3596/4885 |
| US-20060281711-A1 | IL-12 modulatory compounds | IL2, IL4, IL15 | KDM4E 3767/4885ALDH1A1 1007/4885GAA 4353/4885 |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IL15 | KDM4E 3767/4885ALDH1A1 1007/4885GAA 4353/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | KDM4E 2869/4885ALDH1A1 747/4885GAA 2317/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | KDM4E 1015/4885ALDH1A1 3468/4885GAA 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.